Last week, the market was shaken by significant events, including President Trump's announcement of sweeping tariffs, sparking fears of a global economic downturn. Danaher experienced an 11% decline over the same period, paralleling the broader market turmoil. The drastic stock fluctuations were largely attributed to jittery investor sentiment, compounded by the tariffs and resulting trade tensions. As the market tumbled, the Nasdaq also entered bear market territory. Danaher's performance aligns with the general decline observed across major indices, mirroring the S&P 500's notable weekly loss amidst broader economic uncertainty and shifting trade policies.

Buy, Hold or Sell Danaher? View our complete analysis and fair value estimate and you decide.

Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

Over the past five years, Danaher has achieved a total return of 43.55%, reflecting its enduring growth and investment strategies. This includes both share price appreciation and dividends. Despite facing challenges like weak core revenue growth in recent years and issues in its Diagnostics segment, the company maintained a proactive approach by focusing on acquisitions and innovations which poised it well for future growth. Additionally, increased dividends and a robust share repurchase program, exemplified by buybacks worth almost $1.91 billion, have played a role in boosting shareholder returns.

While Danaher's earnings witnessed a yearly downturn, it nevertheless outperformed the US Life Sciences industry's decline over the last year. The company also formed key partnerships, such as with Johns Hopkins University, and maintained its commitment to innovation with initiatives like launching new labs. These efforts underscore Danaher's strategic focus on long-term success, establishing a foundation for stability amidst fluctuating market conditions.

Gain insights into Danaher's outlook and expected performance with our report on the company's earnings estimates.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:DHR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com